Keyphrases
Heart Failure
58%
Pharmacist Perspectives
50%
Copper Cluster
50%
Myosin Activation
50%
Lysine
50%
Medicines Optimisation
50%
Systolic Heart Failure
50%
Colorimetric Immunoassay
50%
Labeling Method
50%
Omecamtiv Mecarbil
50%
Guideline-directed Medical Therapy
50%
Cardiac Myosin
50%
Heart Failure with Preserved Ejection Fraction (HFpEF)
38%
Oklahoma
30%
State Universities
30%
Optimal Dose
30%
University Medical Centre
30%
Patients with Heart Failure
26%
Angiotensin Receptor Blockers
20%
Heart Failure Events
16%
Placebo Groups
16%
Change from Baseline
16%
Placebo
16%
Hazard Ratio
16%
Confidence Interval
16%
Immunoaffinity Assays
12%
Cluster Anions
12%
Downscaling
12%
Application Usage
12%
Sensitivity Threshold
12%
Molecular Weight Range
12%
Violet
12%
Capillary Method
12%
Zone Electrophoresis
12%
Spectrophotometric Method
12%
Elution Rate
12%
Neutral pH
12%
Buffer pH
12%
Binding Interaction
12%
Affinity Labeling
12%
Acetate Buffer
12%
D-penicillamine
12%
Association Constant
12%
Non-biological
12%
Angiotensin Receptor-neprilysin Inhibitor
10%
Emergency Department Services
10%
Inpatient Services
10%
Angiotensin-converting Enzyme Inhibitor (ACEi)
10%
Pharmacist-led Services
10%
New-onset Heart Failure
10%
Medicine and Dentistry
Heart Failure
100%
Systolic Heart Failure
50%
Omecamtiv Mecarbil
50%
Cardiac Myosin
50%
Drug Therapy
50%
Combination Therapy
50%
Optimal Drug Dose
30%
Heart Failure with Reduced Ejection Fraction
30%
Placebo
28%
Cardiovascular System
28%
Angiotensin Receptor Antagonist
20%
Hazard Ratio
14%
Ejection Fraction
14%
Titrimetry
10%
Aldosterone Antagonist
10%
ACE Inhibitor
10%
Enkephalinase Inhibitor
10%
Cardiology
10%
Echocardiography
10%
Spironolactone
10%
Beta Adrenergic Receptor Blocking Agent
10%
Quality Improvement
10%
Emergency Department
10%
Troponin I
7%
Cardiac Troponin
7%
Heart Death
7%
Outpatient
7%
Heart Function
7%
Brain Natriuretic Peptide
7%
Cardiomyopathy
7%
Pharmacokinetics
7%
Heart Ventricle Arrhythmia
7%
Amino Terminal Sequence
7%
Symptom
7%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
100%
Omecamtiv Mecarbil
50%
Systolic Heart Failure
50%
Combination Therapy
50%
Cardiac Myosin
50%
Heart Failure with Reduced Ejection Fraction
30%
Placebo
28%
Angiotensin Receptor Antagonist
20%
Enkephalinase Inhibitor
10%
Dipeptidyl Carboxypeptidase Inhibitor
10%
Aldosterone Antagonist
10%
Spironolactone
10%
Beta Adrenergic Receptor Blocking Agent
10%
Cardiomyopathy
7%
Brain Natriuretic Peptide
7%
Heart Death
7%
Troponin I
7%
Heart Ventricle Arrhythmia
7%
Symptom
7%
Pharmacokinetics
7%